Table 1 Patient characteristics, clinical TNM stage, and treatment response as determined by RECIST following 2 cycles of therapy
Patient no. | Age | Gender | BMI | Stage | T | N | M | Histology | Cycle 2 RECIST response |
|---|---|---|---|---|---|---|---|---|---|
1 | 60 | M | 27.4 | IIB | 2b | 1 | 0 | Squamous | Non-responder (SD) |
2 | 59 | F | 32.3 | IIIA | 3 | 1 | 0 | Squamous | Responder (PR) |
3 | 77 | M | 27.8 | IIA | 1b | 1 | 0 | Adenocarcinoma | Non-responder (SD) |
4 | 50 | M | 25.1 | IIIA | 3 | 2 | 0 | Squamous | Non-responder (SD) |
5 | 55 | M | 34.6 | IIB | 2b | 1 | 0 | Squamous | Non-responder (SD) |
6 | 33 | M | 35.9 | IIA | 2b | 0 | 0 | Adenocarcinoma | Responder (PR) |
7 | 60 | M | 29.1 | IIIA | 1b | 2 | 0 | Adenocarcinoma | Non-responder (SD) |
8 | 45 | F | 17.3 | IIB | 3 | 0 | 0 | Adenocarcinoma | Non-responder (SD) |
9 | 69 | F | 17.6 | IIB | 3 | 0 | 0 | Squamous | Responder (PR) |